{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:44:27Z","timestamp":1758818667442},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10147-009-0899-y","type":"journal-article","created":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T01:21:24Z","timestamp":1256347284000},"page":"436-441","source":"Crossref","is-referenced-by-count":5,"title":["Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors"],"prefix":"10.1007","volume":"14","author":[{"given":"Takumi","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terukazu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Takaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kawauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneharu","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,25]]},"reference":[{"key":"899_CR1","first-page":"2630","volume":"3","author":"E.H. Einhorn","year":"1997","unstructured":"Einhorn EH (1997) Testicular cancer: an oncological success story. Clin Cancer Res 3:2630\u20132632","journal-title":"Clin Cancer Res"},{"key":"899_CR2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1193::AID-CNCR28>3.0.CO;2-W","volume":"77","author":"F. Farhat","year":"1996","unstructured":"Farhat F, Culine S, Theodore C, et al. (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 77:1193\u20131197","journal-title":"Cancer"},{"key":"899_CR3","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1997.15.7.2559","volume":"15","author":"J.A. McCaffrey","year":"1997","unstructured":"McCaffrey JA, Mazumdar M, Bajorin DF, et al. (1997) Ifosfamideand cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559\u20132563","journal-title":"J Clin Oncol"},{"key":"899_CR4","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","volume":"16","author":"P.J. Loehrer Sr","year":"1998","unstructured":"Loehrer PJ Sr, Gonin R, Nichols CR, et al. (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500\u20132504","journal-title":"J Clin Oncol"},{"key":"899_CR5","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","volume":"16","author":"J.L. Pico","year":"2005","unstructured":"Pico JL, Rosti G, Kramar A, et al. (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16:1152\u20131159","journal-title":"Ann Oncol"},{"key":"899_CR6","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","volume":"18","author":"R.J. Motzer","year":"2000","unstructured":"Motzer RJ, Sheinfeld J, Mazumdar M, et al. (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413\u20132418","journal-title":"J Clin Oncol"},{"key":"899_CR7","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","volume":"23","author":"G.V. Kondagunta","year":"2005","unstructured":"Kondagunta GV, Bacik J, Donadio A, et al. (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549\u20136555","journal-title":"J Clin Oncol"},{"key":"899_CR8","doi-asserted-by":"crossref","unstructured":"Miki T, Mizutani Y, Nomoto T, et al. (2006) Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for cisplatin refractory germ cell tumors. Proc Am Soc Clin Oncol (abstract 4587)","DOI":"10.1200\/jco.2006.24.18_suppl.4587"},{"key":"899_CR9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1442-2042.2006.01702.x","volume":"14","author":"N. Nonomura","year":"2007","unstructured":"Nonomura N, Oka D, Nishimura K, et al. (2007) Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol 14:527\u2013531","journal-title":"Int J Urol"},{"key":"899_CR10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","volume":"17","author":"C. Bokemeyer","year":"1999","unstructured":"Bokemeyer C, Gerl A, Schoffski P, et al. (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512\u2013516","journal-title":"J Clin Oncol"},{"key":"899_CR11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","volume":"17","author":"L.H. Einhorn","year":"1999","unstructured":"Einhorn LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17: 509\u2013511","journal-title":"J Clin Oncol"},{"key":"899_CR12","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1200\/JCO.1994.12.11.2277","volume":"12","author":"R.J. Motzer","year":"1994","unstructured":"Motzer RJ, Bajorin DF, Schwartz LH, et al. (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277\u20132283","journal-title":"J Clin Oncol"},{"key":"899_CR13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.annonc.a010473","volume":"7","author":"C. Bokemeyer","year":"1996","unstructured":"Bokemeyer C, Beyer J, Metzner B, et al. (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31\u201334","journal-title":"Ann Oncol"},{"key":"899_CR14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","volume":"20","author":"C. Kollmannsberger","year":"2002","unstructured":"Kollmannsberger C, Rick O, Derigs HG, et al. (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031\u20132037","journal-title":"J Clin Oncol"},{"key":"899_CR15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bjc.66000524","volume":"87","author":"C. Kollmannsberger","year":"2002","unstructured":"Kollmannsberger C, Rick O, Klaproth H, et al. (2002) Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 87:729\u2013732","journal-title":"Br J Cancer"},{"key":"899_CR16","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","volume":"20","author":"S. Hinton","year":"2002","unstructured":"Hinton S, Catalano P, Einhorn LH, et al. (2002) Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20:1859\u20131863","journal-title":"J Clin Oncol"},{"key":"899_CR17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2006.07.7271","volume":"25","author":"L.H. Einhorn","year":"2007","unstructured":"Einhorn LH, Brames MJ, Juliar B, et al. (2007) Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25:513\u2013516","journal-title":"J Clin Oncol"},{"key":"899_CR18","unstructured":"Pizzocaro G, Nicolai N, Salvioni R (2001) Paclitaxel, cisplatin and gemcitabine (TGP) third line therapy in metastatic germ cell tumors (GCT) of the testis. Proc Am Soc Clin Oncol (abstract 773)"},{"key":"899_CR19","first-page":"243","volume":"52","author":"J. Mardiak","year":"2005","unstructured":"Mardiak J, Salek T, Sycova-Mila Z, et al. (2005) Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study. Neoplasma 52:243\u2013247","journal-title":"Neoplasma"},{"key":"899_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00685546","volume":"31","author":"H. Akaza","year":"1992","unstructured":"Akaza H, Togashi M, Nishio Y, et al. (1992) Phase II study of cisdiammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol 31:187\u2013192","journal-title":"Cancer Chemother Pharmacol"},{"key":"899_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF02994087","volume":"26","author":"M. Fukuda","year":"1990","unstructured":"Fukuda M, Shinkai T, Eguchi K, et al. (1990) Phase II study of (glycolate-O,O\u2019) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393\u2013396","journal-title":"Cancer Chemother Pharmacol"},{"key":"899_CR22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cncr.10918","volume":"95","author":"T. Miki","year":"2002","unstructured":"Miki T, Mizutani Y, Nonomura N, et al. (2002) Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95:1879\u20131885","journal-title":"Cancer"},{"key":"899_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.10-1-34","volume":"10","author":"B. Pauwels","year":"2005","unstructured":"Pauwels B, Korst AE, Lardon F, et al. (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10:34\u201351","journal-title":"Oncologist"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-009-0899-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0899-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T06:54:42Z","timestamp":1590216882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-009-0899-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s10147-009-0899-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}